Physician profile
Nadeem Ali
NPI 1922374750
$109,718.83
in general payments reported to CMS, 2019-2025
43 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,675 · 2020: $13K · 2021: $2,514 · 2022: $1,904 · 2023: $4,122 · 2024: $39K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Education: $14K · Food and Beverage: $14K · Consulting Fee: $3,053 · Travel and Lodging: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,390.00 |
| Education | $14,412.41 |
| Food and Beverage | $13,984.09 |
| Consulting Fee | $3,053.22 |
| Travel and Lodging | $2,251.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $62,696.81 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Intuitive Surgical, INC. | $22,014.12 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $9,775.33 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $3,355.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $2,723.94 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,563.94 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $676.15 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $641.26 | 2021-2025 | Tezspire |
| Genzyme Corporation | $623.50 | 2019-2025 | |
| Mylan Specialty L.P. | $578.20 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $543.81 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Philips North America LLC | $513.30 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $494.73 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $413.55 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Novartis Pharmaceuticals Corporation | $279.76 | 2019-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $261.90 | 2025 | Yupelri |
| Merit Medical Systems INC | $254.02 | 2023 | Aeromini Stent and Delivery System, Aero Stent and Delivery System |
| Sunovion Pharmaceuticals INC. | $226.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $225.97 | 2023-2025 | |
| Genentech USA, INC. | $200.58 | 2019-2023 | Xolair |
| Inspire Medical Systems, INC. | $169.87 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $161.51 | 2019-2025 | Keytruda, Winrevair |
| United Therapeutics Corporation | $140.79 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Ani Pharmaceuticals, INC. | $125.90 | 2022-2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $120.91 | 2019-2022 | |
| Erbe USA INC | $113.21 | 2025 | Cryo2 |
| Bayer Healthcare Pharmaceuticals INC. | $110.33 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.54 | 2020-2025 | Glassia, Aralast |
| Jazz Pharmaceuticals INC. | $105.89 | 2019-2025 | |
| Harmony Biosciences LLC | $85.26 | 2023-2024 | Wakix |
| Verona Pharma, INC. | $72.89 | 2025 | Ohtuvayre |
| Adma Biomanufacturing LLC | $63.22 | 2025 | |
| Olympus America INC. | $58.71 | 2025 | |
| Shire North American Group INC | $57.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.16 | 2019-2020 | |
| Pfizer INC. | $27.00 | 2019-2022 | |
| Lilly USA, LLC | $18.22 | 2023 | Mounjaro |
| Csl Behring | $16.82 | 2019 | |
| Axsome Therapeutics, INC. | $16.81 | 2023 | Sunosi |
| Covis Pharma Gmbh | $14.90 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.06 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $13.88 | 2025 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.